KRAS and pancreatic intraductal papillary-mucinous neoplasm: Survival analysis showed that the prognosis of patients was not associated with the mutation status of the KRAS gene in any of the IPMN patients or in the invasive IPMN patients (P = 0.355 and P = 0.996) (Figure 2).